Generic Name
Mesoridazine
Brand Name
Serentil, Lidanil
Class
Antipsychotic (conventional)
Proposed Mechanism(s) of Action
Dopamine 2 receptor blocker.
Indication
Schizophrenia.
Off Label Use
Uncommon.
Side Effects
Serious
QT prolongation, agranulocytosis, seizures, neuroleptic malignant syndrome, ventricular arrhythmia, and sudden death.
Common
Akathisia, neuroleptic-induced deficit syndrome, extrapyramidal symptoms, priapism, galactorrhea, amenorrhea, pigmentary retinopathy, sexual dysfunction, dry mouth, blurred vision, and weight gain.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Readings
Physicians’ Desk Reference (62nd ed.). (2007). Montvale, NJ: Thomson PDR.
Stahl, S. M. (2007). Essential psychopharmacology: The prescriber’s guide (2nd ed.). New York, NY: Cambridge University Press.
Additional Information
Drug Interaction Effects: http://www.drugs.com/drug_interactions.html
Drug Molecule Images: http://www.worldofmolecules.com/drugs/
Free Drug Online and PDA Software: www.epocrates.com
Gene-Based Estimate of Drug interactions: http://mhc.daytondcs.com:8080/cgi bin/ddiD4?ver=4&task=getDrugList
Pill Identification: http://www.drugs.com/pill_identification.html
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this entry
Cite this entry
Courtney, J.C., Akins, C. (2011). Mesoridazine. In: Kreutzer, J.S., DeLuca, J., Caplan, B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-79948-3_1674
Download citation
DOI: https://doi.org/10.1007/978-0-387-79948-3_1674
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-79947-6
Online ISBN: 978-0-387-79948-3
eBook Packages: Behavioral Science